BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 22853444)

  • 1. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
    Tella SH; Gallagher JC
    Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS; Mirkin S; Jenkins SN
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV; Stovall DW
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
    Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
    Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
    Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
    J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
    Mirkin S; Komm BS; Pan K; Chines AA
    Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
    Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
    Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP
    Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S; Currie H; Mikkola TS; Dragon E
    Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
    Pinkerton JV; Komm BS; Mirkin S
    Climacteric; 2013 Dec; 16(6):618-28. PubMed ID: 23805785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in menopausal therapy: the tissue-selective estrogen complex.
    Moore A
    J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.